Document Detail


p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells.
MedLine Citation:
PMID:  15870934     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Histone acetyltransferase and histone deacetylase (HDAC) determine the acetylation status of histones, and thereby control the regulation of gene expression. HDAC inhibitors have been found to inhibit the growth of a variety of tumor cells in vitro and in vivo. We demonstrated previously that the short-chain fatty acid compound butyrate and its derivative tributyrin (both HDAC inhibitors) arrest cell growth and induce differentiation in human neuroblastoma (NB) cells. In the current study we investigated the effect of the HDAC inhibitor valproic acid (VPA) on proliferation and differentiation in human NB cells (SJ-N-KP, AF8). Treatment with VPA resulted in a strong inhibition of cell proliferation and induction of cell differentiation, as revealed by neurite outgrowth and increase of acetylcholinesterase specific activity. Moreover, we addressed the question of whether the cyclin-dependent kinase inhibitors p21(Cip1) and p27(Kip1) are involved in the mechanism of action of members of the short-chain fatty acids class (VPA, sodium butyrate and tributyrin) of HDAC inhibitors, in human NB cells. We demonstrated that p21(Cip1) is a common target of induction of transcription and protein expression for all the three compounds, while only VPA induced a concomitant increase of p27(Kip1) gene expression. These results suggest that p21(Cip1) could be involved in the inhibition of proliferation and induction of differentiation in human NB cells induced by treatment with VPA or tributyrin or sodium butyrate. Moreover, p21(Cip1) could be applied in the molecular monitoring of drug action in the possible therapeutic application of these short-chain fatty acid members of HDAC inhibitors for human NB treatment.
Authors:
Paola Rocchi; Roberto Tonelli; Consuelo Camerin; Stefania Purgato; Raffaele Fronza; Fabrizio Bianucci; Francesco Guerra; Andrea Pession; Anna Maria Ferreri
Related Documents :
16328054 - Saha, a hdac inhibitor, has profound anti-growth activity against non-small cell lung c...
1425354 - Developmental regulation of chromatin composition during mouse embryogenesis: somatic h...
12673114 - Histone deacetylase inhibitors in cancer therapy.
10567654 - Characterization of the transcriptional repressor rbp in epstein-barr virus-transformed...
24239544 - Expression, phosphorylation and function of the rab-gtpase activating protein tbc1d1 in...
22528354 - Derivation, expansion, and characterization of human embryonic stem cell lines from ane...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Oncology reports     Volume:  13     ISSN:  1021-335X     ISO Abbreviation:  Oncol. Rep.     Publication Date:  2005 Jun 
Date Detail:
Created Date:  2005-05-04     Completed Date:  2005-09-19     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  9422756     Medline TA:  Oncol Rep     Country:  Greece    
Other Details:
Languages:  eng     Pagination:  1139-44     Citation Subset:  IM    
Affiliation:
Department of Experimental Pathology, University of Bologna, Bologna, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acetylation
Acetylcholinesterase / metabolism
Butyrates / pharmacology
Carrier Proteins / metabolism
Cell Cycle Proteins / metabolism*
Cell Differentiation / drug effects*
Cell Proliferation / drug effects*
Cyclin-Dependent Kinase Inhibitor p21
Cyclin-Dependent Kinase Inhibitor p27
Enzyme Inhibitors / pharmacology*
Fatty Acids / pharmacology
Gene Expression Regulation / drug effects*
Histone Deacetylase Inhibitors*
Histone Deacetylases / metabolism
Humans
Intracellular Signaling Peptides and Proteins / metabolism
Neurites / drug effects,  metabolism
Neuroblastoma / drug therapy*,  metabolism,  pathology
Triglycerides / pharmacology
Tumor Cells, Cultured
Valproic Acid / pharmacology
Chemical
Reg. No./Substance:
0/Butyrates; 0/CDKN1A protein, human; 0/CDKN1B protein, human; 0/Carrier Proteins; 0/Cell Cycle Proteins; 0/Cyclin-Dependent Kinase Inhibitor p21; 0/Enzyme Inhibitors; 0/Fatty Acids; 0/Histone Deacetylase Inhibitors; 0/Intracellular Signaling Peptides and Proteins; 0/Triglycerides; 147604-94-2/Cyclin-Dependent Kinase Inhibitor p27; 60-01-5/tributyrin; 99-66-1/Valproic Acid; EC 3.1.1.7/Acetylcholinesterase; EC 3.5.1.98/Histone Deacetylases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Identification and characterization of a novel kelch-like gene KLHL15 in silico.
Next Document:  A phase II and pharmacologic study of fluorouracil given by a 1-hour infusion daily for 5 days with ...